MA-SHERLOCK-BIOSCIENCES
23.6.2021 14:32:06 CEST | Business Wire | Press release
The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic while promoting diverse representation in STEM, today announced that its partnerships will increase COVID-19 diagnostic manufacturing capacity by up to 10 million tests per month by year-end. Through multiple license agreements this year with organizations including ALBOT Technologies , Cooper International , LogicInk , Rokline , United PPE and binx health , The 221b Foundation has enabled manufacturing and global distribution in the U.S., United Arab Emirates, India and Singapore, and is in discussions to expand beyond these geographies to increase access for vital diagnostic solutions around the world.
The 221b Foundation was founded to aid in the fight against the global COVID-19 pandemic by enabling access to intellectual property associated with the company’s SHERLOCK™ CRISPR-based technology. Proceeds from third-party sales of SHERLOCK CRISPR COVID-19 products have supported programs that promote racial and gender diversity in STEM, including HMS MEDscience , Scratch and The Akilah Institute .
“As the world mobilized to respond to the COVID-19 pandemic, our mission obligated us to be part of the global solution. The 221b Foundation is one of our most important responses – an open innovation model to provide our comprehensive CRISPR IP estate to expedite the end of the pandemic,” said Rahul Dhanda, co-founder, president and CEO of Sherlock Biosciences. “Since launching the Foundation, we have enabled a variety of use cases from point-of-care to strategic testing centers in the country of Nepal to highly automated clinical environments. We are honored to be meeting this global need while creating pathways for programs that support gender and racial diversity in STEM, a vital step to ensure our industry reflects the communities it serves around the world.”
Since receiving Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration in May 2020 for its Sherlock™ CRISPR SARS-CoV-2 kit – the first FDA-authorized use of CRISPR technology – The 221b Foundation has continued to increase access to the technology through partnerships around the world.
“Since launching The 221b Foundation, we have continued to advance the platform workflow to provide a high-throughput, low cost and incredibly accurate solution to patients worldwide, while advancing the field of CRISPR diagnostics with innovations building on our discovery of new Cas enzymes to enable fully integrated, real-time multiplex testing,” said William J. Blake, Ph.D., Chief Technology Officer, Sherlock Biosciences. “Our and our partners’ assays are highly effective at detecting new, highly transmissible COVID-19 variants, making them a powerful solution to this global public health crisis.”
To learn more about licensing opportunities or our CRISPR SARS-CoV-2 method, contact us directly at sales@sherlock.bio or read our White Paper here .
About The 221b Foundation
The 221b Foundation was founded with the dual mission to assist in the eradication of COVID-19, while supporting racial and gender diversity in STEM. By providing support and intellectual property that enables both non-profit and for-profit entities to develop CRISPR-based diagnostic testing, The 221b Foundation seeks to aid in the fight against the global COVID-19 pandemic while furthering access and diversity in STEM industries. Led by industry experts in the fields of diagnostic testing, STEM and diversity, The 221b Foundation envisions a world where advances in CRISPR technology fuel the innovations that will put an end to the COVID-19 pandemic. For more information, please visit: 221bfoundation.org
.
About Sherlock Biosciences
Sherlock Biosciences is dedicated to providing global access to the simplest and most accurate tests that empower individuals to control their own healthcare. Through its Engineering Biology platforms, the company is developing applications of SHERLOCK™, a CRISPR-based method for “smart amplicon detection,” and INSPECTR™, a synthetic biology-based molecular diagnostics platform that is instrument-free. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including precision oncology, infection identification, food safety, at-home tests and disease detection in the field. In 2020, the company made history with the first FDA-authorized use of CRISPR technology. For more information visit Sherlock.bio
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005110/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kao’s Laurier Launches New Brand Communication Initiative across Asia: Strengthening Global Integration as a Core Brand in Kao’s Asian Business4.3.2026 03:10:00 CET | Press release
Starting on International Women’s Day, March 8, Kao Corporation (TOKYO:4452) will launch new brand communication campaign in nine Asian countries and regions for its feminine sanitary product brand, Laurier, which is the core of its Asian business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303996141/en/ Laurier Campaign Key Visual Laurier aims to help create more supportive and understanding environments around menstruation, so that women can feel more at ease, both physically and emotionally, under the key message “Comfort, Made Together,” which will be implemented simultaneously across Asia. Kao aims to further develop Laurier as a global brand. Laurier, one of the core brands supporting Kao’s consumer care business in Asia, has been promoting globally integrated operations since 2023. Across all nine Asian countries and regions including Japan, Laurier has been working to unify product specifications and consolida
FIFA World Cup 2026™ Mascots and Representatives from the New York New Jersey Host Committee, U.S. Soccer Federation, Mexico Football Federation and Canada Soccer Light the Empire State Building to Celebrate 100 Days to Go Until the FIFA World ...3.3.2026 23:06:00 CET | Press release
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303105064/en/ FIFA World Cup 2026™ Mascots and Representatives from the New York New Jersey Host Committee, U.S. Soccer Federation, Mexico Football Federation and Canada Soccer Light the Empire State Building to Celebrate 100 Days to Go Until the FIFA World Cup 2026™ FIFA World Cup 2026™ Mascots and Representatives from the New York New Jersey Host Committee, U.S. Soccer Federation, Mexico Football Federation and Canada Soccer Light the Empire State Building to Celebrate 100 Days to Go Until the FIFA World Cup 2026™ On Tuesday, March 3, the Empire State Building will rotate in the colors of the flags of the three host countries – the United States, Canada, and Mexico – to mark 100 days to go until the FIFA World Cup 2026™. Earlier today, the Empire State Building hosted a special tower lighting ceremony with Alex Lasry, CEO of the FIFA World Cup 26™ New York New Jersey Host C
SES Publishes 2025 Annual Report3.3.2026 21:41:00 CET | Press release
SES S.A. has today published its 2025 Annual Report, following the announcement of the company’s full year financial results for the 12 months ended 31 December 2025. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry leadership—backed by a track record of bringing innovation “firsts” to market. As a trusted partner to customers and the global space ecosystem, SES is driving impact that goes far beyond coverage. The company is headquartered
Xsolla Expands Global Payment Coverage Across 18 Markets With 6 Trusted Local Payment Methods to Help Developers Reach New Players Worldwide3.3.2026 18:00:00 CET | Press release
Amazon Pay Japan, Zain Cash, Tamara, M-Pesa, Zamtel, and the Aircash app and vouchers are now available through Xsolla Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced a major expansion of its global payments portfolio across 18 markets in Europe, the Middle East, Africa, and Asia. As developers continue to expand into high-growth and emerging markets, this expansion enables developers to reach new paying users, improve conversion rates, and deliver payment experiences tailored to local player preferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303816373/en/ Graphic: Xsolla The newly supported payment methods include:Local Amazon Pay in Japan, with over 100 million registered Amazon Japan accounts, provides fully localized checkout experiences in Japanese Yen Zain Cash in Iraq is expanding access to mobile-first payment options in a rapidly
SES Announces Annual General Meeting of Shareholders3.3.2026 17:42:00 CET | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Annual General Meeting of SES, Société Anonyme, to be held at the Company’s registered office at Château de Betzdorf, L-6815 Betzdorf (the “Company”), Luxembourg, on Thursday 2 April 2026 at 10:30 a.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Presentation by the Chairman of the Board of Directors of the 2025 activities report of the Board of Directors Presentation of the main developments during 2025 and of the outlook Presentation of the audit report Approval of annual financial statements, balance sheet and profit and loss account as of 31 December 2025 Approval of consolidated financial statements as of 31 December 2025 Allocation of 2025 profits and transfers between reserve accounts Discharge of the members of the Board of Directors Determination of the number of Directors Confirmation of the co-optation of Joseph Cohen and determination o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom